Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases

British Journal of Surgery

Volumn 104, Issue 8, 2017, Pages 990-1002

  Zhao, J ^a   van Mierlo, K M C ^a   Gomez Ramirez J ^d   Kim, H ^e   Pilgrim, C H C ^f   Pessaux, P ^g   Rensen, S S ^a   van der Stok, E P ^c   Schaap, F G ^a   Soubrane, O ^h   Takamoto, T ⁱ   Vigano L ^j   Winkens, B ^a   Dejong, C H C ^a,b   Olde Damink, S W M ^a,k   Garcia Sanz I ^d   Martin Perez E ^d   Cho, J Y ^e   Choi, Y R ^e   Phillips, W ^f   Michael, M ^f   Panaro, F ^g   Chenard, M P ^g   Verhoef, C ^c   Grunhagen D J ^c   Vara, J ^l   Scatton, O ^m   Hashimoto, T ⁱ   Makuuchi, M ⁱ   De Rosa, G ⁿ   Ravarino, N ⁿ   more..

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e Seoul National University Bundang Hospital   (South Korea)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g HÔPITAL DE HAUTEPIERRE   (France)

^h BEAUJON HOSPITAL   (France)

ⁱ JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^j HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l INSTITUT BERGONIÉ   (France)

^m PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁿ MAURIZIANO HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CHEMICALLY INDUCED; COLORECTAL TUMOR; COMPLICATION; FATTY LIVER; FEMALE; HUMAN; LENGTH OF STAY; LIVER FAILURE, ACUTE; LIVER NEOPLASMS; LIVER RESECTION; MALE; META ANALYSIS; MIDDLE AGED; MORTALITY; POSTOPERATIVE COMPLICATIONS; PROCEDURES; SECONDARY; TOXIC HEPATITIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMICAL AND DRUG INDUCED LIVER INJURY; COLORECTAL NEOPLASMS; FATTY LIVER; FEMALE; HEPATECTOMY; HUMANS; LENGTH OF STAY; LIVER FAILURE, ACUTE; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS;

EID: 85020254907     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.10572     Document Type: Review

References (64)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359–E386.
2. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23: 2038–2048.
3. Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 2012; 4: 283–301.
4. Scheele J. Hepatectomy for liver metastases. Br J Surg 1993; 80: 274–276.
5. Tanaka K, Adam R, Shimada H, Azoulay D, Lévi F, Bismuth H. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003; 90: 963–969.
6. Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009; 27: 1829–1835.
7. Nordlinger B, Van Cutsem E, Rougier P, Köhne CH, Ychou M, Sobrero A et al.; European Colorectal Metastases Treatment Group. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007; 43: 2037–2045.
8. Robinson SM, Wilson CH, Burt AD, Manas DM, White SA. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19: 4287–4299.
9. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94: 274–286.
10. Rubbia-Brandt L, Lauwers GY, Wang H, Majno PE, Tanabe K, Zhu AX et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010; 56: 430–439.
11. Viganò L, Rubbia-Brandt L, De Rosa G, Majno P, Langella S, Toso C et al. Nodular regenerative hyperplasia in patients undergoing liver resection for colorectal metastases after chemotherapy: risk factors, preoperative assessment and clinical impact. Ann Surg Oncol 2015; 22: 4149–4157.
12. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007; 110: 2761–2767.
13. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065–2072.
14. Khan AZ, Morris-Stiff G, Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg 2009; 16: 137–144.
15. Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008; 247: 118–124.
16. Pilgrim CH, Satgunaseelan L, Pham A, Murray W, Link E, Smith M et al. Correlations between histopathological diagnosis of chemotherapy-induced hepatic injury, clinical features, and perioperative morbidity. HPB 2012; 14: 333–340.
17. Viganò L, Ravarino N, Ferrero A, Motta M, Torchio B, Capussotti L. Prospective evaluation of accuracy of liver biopsy findings in the identification of chemotherapy-associated liver injuries. Arch Surg 2012; 147: 1085–1091.
18. Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24: 4983–4990.
19. Komori H, Beppu T, Baba Y, Horino K, Imsung C, Masuda T et al. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients. Int J Clin Oncol 2010; 15: 263–270.
20. Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007; 11: 860–868.
21. Sahajpal A, Vollmer CM, Dixon E, Chan EK, Wei A, Cattral MS et al. Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. J Surg Oncol 2007; 95: 22–27.
22. Makowiec F, Möhrle S, Neeff H, Drognitz O, Illerhaus G, Opitz OG et al. Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases. J Gastrointest Surg 2011; 15: 153–164.
23. Kandutsch S, Klinger M, Hacker S, Wrba F, Gruenberger B, Gruenberger T. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol 2008; 34: 1231–1236.
24. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264–269, W264.
25. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–2012.
26. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460–466.
27. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–1321.
28. Vreuls CP, Van Den Broek MA, Winstanley A, Koek GH, Wisse E, Dejong CH et al. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases. Histopathology 2012; 61: 314–318.
29. van Mierlo KMC, Zhao J, Kleijnen J, Rensen SS, Schaap FG, Dejong CHC et al. The influence of chemotherapy-associated sinusoidal dilatation on short-term outcome after partial hepatectomy for colorectal liver metastases: a systematic review with meta-analysis. Surg Oncol 2016; 25: 298–307.
30. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810–820.
31. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205–213.
32. van den Broek MA, van Dam RM, van Breukelen GJ, Bemelmans MH, Oussoultzoglou E, Pessaux P et al. Development of a composite endpoint for randomized controlled trials in liver surgery. Br J Surg 2011; 98: 1138–1145.
33. Balzan S, Belghiti J, Farges O, Ogata S, Sauvanet A, Delefosse D et al. The ‘50–50 criteria’ on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg 2005; 242: 824–828.
34. Couinaud C. Liver anatomy: portal (and suprahepatic) or biliary segmentation. Dig Surg 1999; 16: 459–467.
35. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med 2013; 158: 280–286.
36. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006; 144: 427–437.
37. Debray TP, Moons KG, Abo-Zaid GM, Koffijberg H, Riley RD. Individual participant data meta-analysis for a binary outcome: one-stage or two-stage? PLoS One 2013; 8: e60650.
38. Abo-Zaid G, Guo B, Deeks JJ, Debray TP, Steyerberg EW, Moons KG et al. Individual participant data meta-analyses should not ignore clustering. J Clin Epidemiol 2013; 66: 865–873.e864.
39. Gómez-Ramírez J, Martín-Pérez E, Amat CG, Sanz IG, Bermejo E, Rodríguez A et al. Influence of pre-surgical chemotherapy on liver parenchyma and post-surgical outcome of patients subjected to hepatectomy due to colorectal carcinoma metastases. Cir Esp 2010; 88: 404–412.
40. Nam SJ, Cho JY, Lee HS, Choe G, Jang JJ, Yoon YS et al. Chemotherapy-associated hepatopathy in Korean colorectal cancer liver metastasis patients: oxaliplatin-based chemotherapy and sinusoidal injury. Korean J Pathol 2012; 46: 22–29.
41. Pessaux P, Marzano E, Casnedi S, Bachellier P, Jaeck D, Chenard MP. Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study. World J Surg 2010; 34: 2765–2772.
42. Soubrane O, Brouquet A, Zalinski S, Terris B, Brézault C, Mallet V et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg 2010; 251: 454–460.
43. Takamoto T, Hashimoto T, Sano K, Maruyama Y, Inoue K, Ogata S et al. Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis. Ann Surg Oncol 2010; 17: 2747–2755.
44. van der Pool AE, Marsman HA, Verheij J, Ten Kate FJ, Eggermont AM, Ijzermans JN et al. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases. J Surg Oncol 2012; 106: 892–897.
45. Schiffer E, Frossard JL, Rubbia-Brandt L, Mentha G, Pastor CM. Hepatic regeneration is decreased in a rat model of sinusoidal obstruction syndrome. J Surg Oncol 2009; 99: 439–446.
46. Hubert C, Dahrenmoller C, Marique L, Jabbour N, Gianello P, Leclercq I. Hepatic regeneration in a rat model is impaired by chemotherapy agents used in metastatic colorectal cancer. Eur J Surg Oncol 2015; 41: 1471–1478.
47. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183–1192.
48. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999; 282: 1659–1664.
49. Yang SQ, Lin HZ, Mandal AK, Huang J, Diehl AM. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. Hepatology 2001; 34: 694–706.
50. Wiggans MG, Lordan JT, Shahtahmassebi G, Aroori S, Bowles MJ, Stell DA. The interaction between diabetes, body mass index, hepatic steatosis, and risk of liver resection: insulin dependent diabetes is the greatest risk for major complications. HPB Surg 2014; 2014: 586159.
51. Reddy SK, Marsh JW, Varley PR, Mock BK, Chopra KB, Geller DA et al. Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case–control study. Hepatology 2012; 56: 2221–2230.
52. McCormack L, Petrowsky H, Jochum W, Furrer K, Clavien PA. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case–control study. Ann Surg 2007; 245: 923–930.
53. Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003; 7: 1034–1044.
54. Rubbia-Brandt L, Tauzin S, Brezault C, Delucinge-Vivier C, Descombes P, Dousset B et al. Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans. Mol Cancer Ther 2011; 10: 687–696.
55. Farrell GC, Teoh NC, McCuskey RS. Hepatic microcirculation in fatty liver disease. Anat Rec (Hoboken) 2008; 291: 684–692.
56. Brouquet A, Benoist S, Julie C, Penna C, Beauchet A, Rougier P et al. Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 2009; 145: 362–371.
57. Kollmar O, Corsten M, Scheuer C, Vollmar B, Schilling MK, Menger MD. Portal branch ligation induces a hepatic arterial buffer response, microvascular remodeling, normoxygenation, and cell proliferation in portal blood-deprived liver tissue. Am J Physiol Gastrointest Liver Physiol 2007; 292: 1534–1542.
58. Matsuo K, Murakami T, Kawaguchi D, Hiroshima Y, Koda K, Yamazaki K et al. Histologic features after surgery associating liver partition and portal vein ligation for staged hepatectomy versus those after hepatectomy with portal vein embolization. Surgery 2016; 159: 1289–1298.
59. van Mierlo KM, Schaap FG, Dejong CH, Olde Damink SW. Liver resection for cancer: new developments in prediction, prevention and management of postresectional liver failure. J Hepatol 2016; 65: 1217–1231.
60. Farid SG, White A, Khan N, Toogood GJ, Prasad KR, Lodge JP. Clinical outcomes of left hepatic trisectionectomy for hepatobiliary malignancy. Br J Surg 2016; 103: 249–256.
61. Viganò L, Capussotti L, De Rosa G, De Saussure WO, Mentha G, Rubbia-Brandt L. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg 2013; 258: 731–742.
62. Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 2011; 18: 421–430.
63. Khoo E, O'Neill S, Brown E, Wigmore SJ, Harrison EM. Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases. HPB 2016; 18: 485–493.
64. Schadde E, Ardiles V, Robles-Campos R, Malago M, Machado M, Hernandez-Alejandro R et al.; ALPPS Registry Group. Early survival and safety of ALPPS: first report of the International ALPPS Registry. Ann Surg 2014; 260: 829–836.